Atorvastatin reduces sympathetic activity in patients with chronic kidney disease

Journal of Hypertension

Volumn 29, Issue 11, 2011, Pages 2176-2180

  Siddiqi, Laima ^a   Joles, Jaap A ^a   Oey, P Liam ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

aliskiren; atorvastatin; chronic kidney disease; muscle sympathetic nerve activity; sympathetic nerve activity

Indexed keywords

ALISKIREN; ATORVASTATIN; DIURETIC AGENT; FUROSEMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MUSCLE SYMPATHETIC NERVE ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE;

EID: 80054106555     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834ae3c7     Document Type: Article

References (22)

1. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918. (Pubitemid 23006966)
2. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706. (Pubitemid 38405571)
3. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14:3239-3244. (Pubitemid 37509299)
4. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15:524-537. (Pubitemid 38294782)
5. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65:1568-1576. (Pubitemid 38591003)
6. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27:1341-1349.
7. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430. (Pubitemid 36150866)
8. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328. (Pubitemid 29196594)
9. Neumann J, Ligtenberg G, Klein IH, Boer P, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49:506-510.
10. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15:2902-2907. (Pubitemid 41103399)
11. Szramka M, Harriss L, Ninnio D, Windebank E, Brack J, Skiba M, Krum H. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int J Cardiol 2007; 117:287-291. (Pubitemid 46452775)
12. Sinski M, Lewandowski J, Ciarka A, Bidiuk J, Abramczyk P, Dobosiewicz A, Gaciong Z. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol Pol 2009; 67:613-620.
13. Gomes ME, Lenders JW, Bellersen L, Verheugt FW, Smits P, Tack CJ. Sympathoinhibitory effect of statins in chronic heart failure. Clin Auton Res 2010; 20:73-78.
14. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979; 59:919-957. (Pubitemid 10191396)
15. Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22:208-215.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
17. Lewandowski J, Sinski M, Bidiuk J, Abramczyk P, Dobosiewicz A, Ciarka A, Gaciong Z. Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res 2010; 33:1038-1043.
18. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant 2011; 26:2930-2934.
19. Joles JA. Statins and small GTPases: Koch's postulates and chronic kidney disease. Nephrol Dial Transplant 2008; 23:433-438. (Pubitemid 351767639)
20. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112:1763-1770. (Pubitemid 41368152)
21. Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010; 11:2635-2650.
22. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12:2427-2433. (Pubitemid 33021120)